These potential drugs have included drugs based on their promising effects against severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or on their ability to block host target proteins, such as angiotensin-converting enzyme 2 (ACE2), which may be a SARS receptor (1). This evidence concerns the gene ACE2 and severe acute respiratory syndrome.